Caring Brands (CABR) investor relations material

Executive summary

• Focused on OTC and cosmetic wellness products, with a pipeline including hair loss, eczema, psoriasis, vitiligo, and suncare solutions.

• Still in early commercialization; minimal revenue generated in the quarter and year-to-date.

• Significant increase in operating expenses, mainly due to stock-based compensation and professional service fees.

• Undergoing compliance and legal settlements, including share repurchases and PIPE financing.

Financial highlights

• Revenue for Q2 2026 was $0, compared to $1,587 in Q2 2025; six-month revenue was $0 vs. $3,056 year-over-year.

• Q2 2026 net loss attributable to common stockholders was $935,019, up from $660,583 in Q2 2025.

• Six-month net loss attributable to common stockholders was $4,798,070, compared to $1,199,353 year-over-year.

• Operating expenses for Q2 2026 were $638,737, down 3% from Q2 2025; six-month operating expenses rose 97% to $2,360,236.

• Cash and cash equivalents at June 30, 2026 were $1,820,365, down from $2,189,232 at year-end 2025.

Outlook and guidance

• Management believes current cash is sufficient for at least the next twelve months but may seek additional capital for growth or strategic initiatives.

• No formal revenue guidance provided; business remains in development and commercialization phase.